Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Next Previous
Trial Profile

AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ambrisentan (Primary) ; Tadalafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms AMBITION
  • Sponsors Gilead Sciences; GlaxoSmithKline; GSK

Most Recent Events

  • 19 Nov 2020 Results comparing effectiveness of macitentan versus ambrisentan in monotherapy and combination therapy, utilizing Bucher's indirect treatment comparison (ITC) method with individual patient data from the SERAPHIN study and aggregate data from the AMBITION study, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
  • 16 Sep 2020 Results of pooled analysis of three studies (AMBITION, SERAPHIN, and GRIPHON) comparing validated clinical scales of risk (COMPERA, the French score, and REVEAL 2.0) to identify patients that are likely to experience a clinical worsening event for trial enrichment, published in the American Journal of Respiratory and Critical Care Medicine.
  • 01 Sep 2020 Results of post-hoc analysis (n=605) presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top